ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1499

Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study

René-Marc Flipo 1, Florence Tubach 2, Jean Ouaniche 3, Philippe Goupille4, Eric Lespessailles 5, Najat Gouyette 6, Naoual Harid 7, Jean-Marie Fayette 8, Philippe Bertin 9 and Bruno Fautrel 10, 1Roger Salengro University-Hospital, Lille , France, Lille, France, 2Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, 3Private Practice , Toulon, France, Toulon, France, 4Tours University-Hospital, Tours, France, Tours, France, 5Orléans Regional Hospitals, Orléans ,France, Orléans, France, 6MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, 7MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, 8ClinSearch, Malakoff, France, Malakoff, Ile-de-France, France, 9Limoges University-Hospital , Limoges, France, Limoges, France, 10Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-TNF therapy, axial spondyloarthritis, Biologic drugs, clinical practice and Disease Activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received biologics. However, clinical studies of GLM in axial spondyloarthritis (axSpA) are lacking. Using data from the GO PRACTICE study, we examined GLM persistence in patients with axSpA.
The primary objective of the study was to estimate GLM persistence at 2 years from initial prescription, as a first line of treatment (in biologic naïve patients: BN) and as a second or further line of treatment (in biologic pretreated patients: BP). Secondary outcomes included evaluations of changes over 2 years in 1) clinical disease activity, and 2) patient-reported disease activity, pain, functional ability and quality of life (QoL).

Methods: This was an observational, prospective, multicenter French study, that recruited adult patients with RA, psoriatic arthritis or axSpA, who were newly prescribed GLM. Patients were followed-up over 2 years; data were collected at baseline, 1 year and 2 years. This abstract presents findings originating from the axSpA cohort of the GO PRACTICE study. GLM persistence was estimated with the Kaplan-Meier method. Clinical disease activity was assessed with the Ankylosing Spondylitis Disease Activity Score (ASDAS) and patient-reported disease activity was evaluated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Pain was evaluated using a visual analogue scale (VAS), functional ability with the Health Assessment Questionnaire (HAQ) and QoL with the EQ-5D and SF-12 questionnaires.

Results: From January 2015 to March 2016, 478 axSpA patients (constituting 63% of the total cohort) from 134 sites were included in the study. Mean age was 43 years and 55% were female; 61% were BN (n=291) and 39% were BP (n=187). Mean duration of axSpA illness was 5.5 and 10.7 years in BN and BP patients, respectively (p < .001). At baseline, most were prescribed 50 mg GLM monthly (97%); DMARDs, corticosteroids and NSAIDs or analgesics were co-prescribed to 34%,17% and 90% of axSpA patients, respectively. GLM persistence over 2 years was significantly higher in BN than BP patients (59.2% vs 45.1%, logrank p < .01). For BN and BP patients persisting on GLM at 2 years, disease activity (Table 1) and patient-reported outcomes showed significant improvements, with improvements being more important in BN patients. GLM was well tolerated in axSpA patients (n=478), with 46 (9.6%) discontinuing due to intolerance. In the BN group, 18 patients (6.2%) discontinued GLM due to primary treatment failure, compared to 28 BP patients (15%). GLM was re-prescribed to 213 (88%) of the 241 patients persisting on GLM at 2-years. Post-hoc multivariate analysis showed that being female was a risk factor for GLM discontinuation in axSpA (HR1.9, IC95% 1.4-2.6).

Conclusion: Golimumab is associated with clinical improvements and good persistence in patients with axial spondyloarthritis, especially those who are biologic naïve

References:

1.Smolen JS, et al; Arthritis research & therapy 2015,17:14

Disease activity scores at baseline and 2 years for biologics naïve -BN- and biologics pretreated -BP- axial spondyloarthritis -axSpA- patients who were persisting on golimumab.

Kaplan-Meier plots showing the cumulative persistence probability of golimumab over 24 months in axial spondyloarthritis -axSpA- patients who were biologics naïve -BN- and biologics pretreated -BP-.


Disclosure: R. Flipo, MSD, 5, Sanofi, 5; F. Tubach, MSD, 5; J. Ouaniche, MSD, 5; P. Goupille, AbbVie, 5, Amgen, 5, Biogaran, 5, BMS, 5, Celgene, 5, Eli Lilly, 5, Hospira, 5, Janssen-Cilag, 5, MSD, 5, Pfizer, 5, Sanofi-Genzyme, 5, UCB, 5; E. Lespessailles, MSD, 5; N. Gouyette, MSD, 3; N. Harid, MSD, 3; J. Fayette, MSD, 9; P. Bertin, MSD, 5; B. Fautrel, AbbVie, 2, 5, 8, Biogen, 5, 8, BMS, 5, 8, Boehringer Ingelheim, 8, Celgene, 5, 8, Eli Lilly and Company, 2, 5, Janssen, 5, 8, Lilly, 8, Medac, 5, 8, MSD, 2, 5, 8, NORDIC Pharma, 5, 8, Novartis, 5, 8, Pfizer, 2, 5, 8, Roche, 5, 8, Sanofi-Aventis, 5, SOBI, 5, 8, UCB, 5, 8.

To cite this abstract in AMA style:

Flipo R, Tubach F, Ouaniche J, Goupille P, Lespessailles E, Gouyette N, Harid N, Fayette J, Bertin P, Fautrel B. Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/golimumab-persistence-in-biologic-naive-and-non-naive-patients-with-axial-spondyloarthritis-results-of-the-go-practice-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/golimumab-persistence-in-biologic-naive-and-non-naive-patients-with-axial-spondyloarthritis-results-of-the-go-practice-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology